Projects / Antibodies in immune-mediated diseases / Multiple Sclerosis

Innovative techniques for antibody detection in MS


In collaboration with:

Toscana Biomarkers Srl, I-53100 Siena, Italy

Feliciana Real-Fernández

Institut de Chimie Moleculaire (ICMUB, UMR CNRS 5260), University of Burgundy, France

Sylvain Jugè

In multiple sclerosis there is a need to develop non-invasive, sensitive, simple new techniques for the clinical routine. In fact quantitative and qualitative measurements of autoantibodies are crucial in the management of MS, particularly in the development and clinical evaluation of personalized therapeutic treatments. In order to address this challenge we implemented a new electrochemical technique for autoantibody recognition in MS, using beta-turn glucosylated peptide analogues properly modified at N-terminus with new ferrocenyl derivatives as electrochemical probes to be used in cyclic voltammetry measurements in solution and/or grafting peptides on a gold electrode. In fact electrochemistry, as detection technique of biological and clinical assays, can shorten the time of the analyses and increase the reliability of the biological assays, such as ELISA.    

Potential difference between the electrochemical response on the glucosylated peptides (black and green) and the unglucosylated ones  (red and blue)     

Moreover to avoid non reproducible or non interpretable results due to operator-dependent procedures, industry requires not only fast, but also sensitive techniques particularly useful for quantitative determination of autoantibodies. To this aim, we evaluated the feasibility of a biosensor technology based on surface plasmon resonance. In particular a glycopeptide-based biosensor to detect MS specific antibodies in sera has been developed immobilizing the N-glucosylated beta-turn peptide antigen on a gold sensor chip. The method was optimized for real-time specific autoantibody detection directly on sera.

In the picture it is reported a column scatter and mean values of anti-CSF114(Glc) antibodies in MS versus blood donors (BD) measured by surface plasmon resonance